The development of ICOS × PD-1 therapeutic bispecific antibody for colorectal cancer immunotherapy is the goal of this program.
Justification for the program:
In a range of cancer types, blocking the PD-1 / L1 axis has demonstrated long-lasting effects and increased overall survival. For relapsed patients, there is still a sizable unmet demand.
In the tumor microenvironment (TME), activated T cells (such as TEff and TReg cells) express ICOS, a costimulatory molecule. According to studies, ICOS agonism may enhance TEff cell viability and IFNy release, which would activate the T cell-dependent tumor eradication process.
Presently available therapeutic antibody treatment approaches for various combinations of PD1/costimulatory molecules have demonstrated strong efficacy in cancer immunotherapy.
For more: https://www.creative-biola...
Justification for the program:
In a range of cancer types, blocking the PD-1 / L1 axis has demonstrated long-lasting effects and increased overall survival. For relapsed patients, there is still a sizable unmet demand.
In the tumor microenvironment (TME), activated T cells (such as TEff and TReg cells) express ICOS, a costimulatory molecule. According to studies, ICOS agonism may enhance TEff cell viability and IFNy release, which would activate the T cell-dependent tumor eradication process.
Presently available therapeutic antibody treatment approaches for various combinations of PD1/costimulatory molecules have demonstrated strong efficacy in cancer immunotherapy.
For more: https://www.creative-biola...
9 months ago
